Aurobindo Pharma plunges 9% as USFDA issues 14 observations

Aurobindo Pharma plunges 9% as USFDA issues 14 observations

By, Admin 15 November 2019

NEW DELHI: Shares of Aurobindo Pharma tumbled 9 per cent in Thursday’s trade after US drug regulator issued 'Form 483' with 14 observations to the company's injectable formulation manufacturing facility at Pashamylaram, Hyderabad. The Unit IV of the facility was inspected by USFDA from November 4 to November 13. “We believe that none of these observations are related to data integrity issues. The company will respond to the USFDA within the stipulated timeline,” Aurobindo Pharma said in a note. But the statement could not stop the scrip from falling 8.9 per cent to Rs 394.70. This was the lowest level for the scrip since October 7. The drugmaker reported a 4.6 per cent rise in its consolidated net profit at Rs 639.5 crore for the quarter ended September 30, 2019. The company had posted a net profit of Rs 611.4 crore in the corresponding period in previous fiscal, Aurobindo Pharma said in a BSE filing. Aurobindo Pharma's revenue increased 17.9 per cent to Rs 5,600.5 crore during the quarter under review from Rs 4,751.4 crore in the year-ago period, it added. The company’s board approved an interim dividend of Re 1.25 per equity share of Re 1 for the year 2019-20. "We had another quarter of healthy performance where we continued to grow in US and Europe, which are our focused geographies," Aurobindo Pharma Managing Director N Govindarajan said.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!